LINC00426, a novel m6A-regulated long non-coding RNA, induces EMT in cervical cancer by binding to ZEB1.
暂无分享,去创建一个
Shizhi Wang | Siyuan Shen | Bingjia Yu | M. Tang | Hua Jin | Jing-Bo Hu | Ying Zhang | Xing Zhang | Wenjing Yan | Shuqian Xie | Haohan Liu | Yun Gu | Xue-Bo Chen | Fengying Liu | Xiuting Li | Yamei Nie | Shizhi Wang | Xue Chen
[1] Y. Li,et al. Managing Cancer Drug Resistance from the Perspective of Inflammation , 2022, Journal of oncology.
[2] Qiaojun He,et al. Tackling drug resistance in ovarian cancer with epigenetic targeted drugs. , 2022, European journal of pharmacology.
[3] Jinghan Zhu,et al. Identification of an EMT-related lncRNA signature and LINC01116 as an immune-related oncogene in hepatocellular carcinoma , 2022, Aging.
[4] Hui Hu,et al. Knockdown of lncRNA FOXD2-AS1 Inhibits Proliferation, Migration, and Drug Resistance of Breast Cancer Cells , 2021, Computational and mathematical methods in medicine.
[5] J. Ding,et al. Increased ATG5 Expression Predicts Poor Prognosis and Promotes EMT in Cervical Carcinoma , 2021, Frontiers in Cell and Developmental Biology.
[6] M. Fan,et al. LncRNA MALAT1 Facilitates Ovarian Cancer Progression through Promoting Chemoresistance and Invasiveness in the Tumor Microenvironment , 2021, International journal of molecular sciences.
[7] Shaoyun Chen,et al. m6A methyltransferase METTL3-mediated lncRNA FOXD2-AS1 promotes the tumorigenesis of cervical cancer , 2021, Molecular therapy oncolytics.
[8] Zhi-wei Wang,et al. METTL3 increases cisplatin chemosensitivity of cervical cancer cells via downregulation of the activity of RAGE , 2021, Molecular therapy oncolytics.
[9] Guanbin Song,et al. Inhibiting the redox function of APE1 suppresses cervical cancer metastasis via disengagement of ZEB1 from E-cadherin in EMT , 2021, Journal of experimental & clinical cancer research : CR.
[10] A. Jemal,et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.
[11] Ling Wei,et al. Noncoding RNAs in gastric cancer: implications for drug resistance , 2020, Molecular Cancer.
[12] Jacques Ferlay,et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis , 2019, The Lancet. Global health.
[13] Q. Kan,et al. The interplay between m6A RNA methylation and noncoding RNA in cancer , 2019, Journal of Hematology & Oncology.
[14] M. Najafi,et al. Cancer stem cell (CSC) resistance drivers. , 2019, Life sciences.
[15] S. Jaffrey,et al. Reading, writing and erasing mRNA methylation , 2019, Nature Reviews Molecular Cell Biology.
[16] Jie Shen,et al. LncRNA XIST promotes pancreatic cancer migration, invasion and EMT by sponging miR-429 to modulate ZEB1 expression. , 2019, The international journal of biochemistry & cell biology.
[17] Fan Mo,et al. The lncRNA PVT1 regulates nasopharyngeal carcinoma cell proliferation via activating the KAT2A acetyltransferase and stabilizing HIF-1α , 2019, Cell Death & Differentiation.
[18] Qifeng Yang,et al. LncRNA–CDC6 promotes breast cancer progression and function as ceRNA to target CDC6 by sponging microRNA‐215 , 2018, Journal of cellular physiology.
[19] Yu-Sheng Chen,et al. Dynamic transcriptomic m6A decoration: writers, erasers, readers and functions in RNA metabolism , 2018, Cell Research.
[20] Mohini Singh,et al. EMT: Mechanisms and therapeutic implications , 2017, Pharmacology & therapeutics.
[21] Longhua Chen,et al. A novel lncRNA uc.134 represses hepatocellular carcinoma progression by inhibiting CUL4A-mediated ubiquitination of LATS1 , 2017, Journal of Hematology & Oncology.
[22] A. Tramontano,et al. The Snail repressor recruits EZH2 to specific genomic sites through the enrollment of the lncRNA HOTAIR in epithelial-to-mesenchymal transition , 2016, Oncogene.
[23] S. Dhamija,et al. From junk to master regulators of invasion: lncRNA functions in migration, EMT and metastasis , 2016, International journal of cancer.
[24] S. Alahari,et al. Regulation of epithelial-mesenchymal transition through epigenetic and post-translational modifications , 2016, Molecular Cancer.
[25] M. Ibrahim,et al. Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp , 2015, Cancer Cell International.
[26] Rajvir Dahiya,et al. Long Noncoding RNA MALAT1 Promotes Aggressive Renal Cell Carcinoma through Ezh2 and Interacts with miR-205. , 2015, Cancer research.
[27] Li-juan Wang,et al. LncRNA-ATB promotes trastuzumab resistance and invasion-metastasis cascade in breast cancer , 2015, Oncotarget.
[28] A. Jemal,et al. Cancer treatment and survivorship statistics, 2014 , 2014, CA: a cancer journal for clinicians.
[29] Yongzhan Nie,et al. Long Noncoding RNA MRUL Promotes ABCB1 Expression in Multidrug-Resistant Gastric Cancer Cell Sublines , 2014, Molecular and Cellular Biology.
[30] Udo Schumacher,et al. Epithelial-mesenchymal transition: focus on metastatic cascade, alternative splicing, non-coding RNAs and modulating compounds , 2013, Molecular Cancer.
[31] Howard Y. Chang,et al. Control of somatic tissue differentiation by the long non-coding RNA TINCR , 2012, Nature.
[32] J. Settleman,et al. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer , 2010, Oncogene.
[33] C. Ponting,et al. Evolution and Functions of Long Noncoding RNAs , 2009, Cell.
[34] S. Coughlin,et al. Burden of cervical cancer in the United States, 1998–2003 , 2008, Cancer.
[35] G. Goodall,et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1 , 2008, Nature Cell Biology.
[36] J. Massagué,et al. Epithelial-Mesenchymal Transitions Twist in Development and Metastasis , 2004, Cell.